sar441566
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2022 (NCT05453942)
Timeline
Indications
Mechanism of action
- TNF-alphaANTAGONIST
TNFA
Chemistry & pharmacology
Loading structure…
SMILES
CN1C(=O)c2cccc(OC(F)F)c2[C@H]2C[C@@H]1c1nc3ccc(-c4cnc(C5(N)CCC5)nc4)cc3n12- Mol. weight
- 502.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068043 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07222189 | Phase 2 | Dec 24, 2025 | Sanofi |
| NCT07272629 | Phase 1 | Dec 3, 2025 | Sanofi |
| NCT06867094 | Phase 2 | Mar 25, 2025 | Sanofi |
| NCT06637631 | Phase 2 | Nov 19, 2024 | Sanofi |
| NCT06073093 | Phase 2 | Nov 7, 2023 | Sanofi |
| NCT06073119 | Phase 2 | Oct 26, 2023 | Sanofi |
| NCT05844735 | Phase 1 | May 22, 2023 | Sanofi |
| NCT05858788 | Phase 1 | May 15, 2023 | Sanofi |
| NCT05453942 | Phase 1 | Jul 12, 2022 | Sanofi |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 9 | 9 | 2 | 2022 |
1 organizations
Page 1 / 1